Edwards Lifesciences Hits Day High with Strong 3.28% Intraday Surge

Edwards Lifesciences Corp., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable uptick in its stock price, gaining 3.28% on February 24, 2026. The stock reached an intraday high of USD 83.02, reflecting a strong performance relative to the broader market, as the S&P 500 only increased by 0.69% on the same day. Over the past week, Edwards Lifesciences has shown an impressive 8.61% increase, significantly outperforming the S&P 500's 1.07% rise. However, the stock's performance over the past month has been slightly negative, with a decline of 1.51%. In terms of annual performance, the stock has generated a return of 12.41%, closely trailing the S&P 500's 12.95%. Financially, Edwards Lifesciences boasts a high return on equity (ROE) of 22.80%, indicating effective management efficiency. The company maintains a low debt-to-equity ratio, which is favorable for its financial health. Despite some fluctuations in performance metrics, the stock is currently trading at a fair valuation compared to its peers, with a price-to-book ratio of 4.62.